These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31062169)

  • 1. Genetic regulation of dimethylarginines and endothelial dysfunction in rheumatoid arthritis.
    Dimitroulas T; Kitas GD
    Amino Acids; 2019 Jul; 51(7):983-990. PubMed ID: 31062169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variations in the alanine-glyoxylate aminotransferase 2 (AGXT2) gene and dimethylarginines levels in rheumatoid arthritis.
    Dimitroulas T; Hodson J; Panoulas VF; Sandoo A; Smith J; Kitas G
    Amino Acids; 2017 Jun; 49(6):1133-1141. PubMed ID: 28357606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation.
    Dimitroulas T; Hodson J; Sandoo A; Smith J; Kitas GD
    Arthritis Res Ther; 2017 Feb; 19(1):32. PubMed ID: 28183353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric and symmetric dimethylarginine concentration as an indicator of cardiovascular diseases in rheumatoid arthritis patients: a systematic review and meta-analysis of case-control studies.
    Zafari P; Zarifian A; Alizadeh-Navaei R; Taghadosi M; Rafiei A; Samimi Z; Niksolat F
    Clin Rheumatol; 2020 Jan; 39(1):127-134. PubMed ID: 31376089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis.
    Chandrasekharan UM; Wang Z; Wu Y; Wilson Tang WH; Hazen SL; Wang S; Elaine Husni M
    Arthritis Res Ther; 2018 Jun; 20(1):123. PubMed ID: 29884228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
    Mangoni AA; Tommasi S; Sotgia S; Zinellu A; Paliogiannis P; Piga M; Cauli A; Pintus G; Carru C; Erre GL
    Curr Pharm Des; 2021; 27(18):2131-2140. PubMed ID: 33413061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo microvascular and macrovascular endothelial function is not associated with circulating dimethylarginines in patients with rheumatoid arthritis: a prospective analysis of the DRACCO cohort.
    Dimitroulas T; Sandoo A; Hodson J; Smith JP; Kitas GD
    Scand J Clin Lab Invest; 2016 Jul; 76(4):331-7. PubMed ID: 27166512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
    Böger RH
    Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symmetric dimethylarginine (SDMA) serum levels in rheumatoid arthritis: correlations with insulin resistance and disease activity scores.
    Dimitroulas T; Hodson J; Sandoo A; Smith J; Kitas GD
    Amino Acids; 2015 Sep; 47(9):1995-2004. PubMed ID: 25772817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.
    Dimitroulas T; Sandoo A; Kitas GD
    Int J Mol Sci; 2012 Sep; 13(10):12315-35. PubMed ID: 23202900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial Dysfunction and Inflammation: Immunity in Rheumatoid Arthritis.
    Yang X; Chang Y; Wei W
    Mediators Inflamm; 2016; 2016():6813016. PubMed ID: 27122657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
    Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
    Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study.
    Dimitroulas T; Hodson J; Sandoo A; Smith JP; Douglas KM; Kitas GD
    Mediators Inflamm; 2015; 2015():796562. PubMed ID: 26543327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput quantitation of serological dimethylarginines by LC/MS/MS: Potential cardiovascular biomarkers for rheumatoid arthritis.
    Huang Q; Liu Y; Cheng Y; Jia F; Pu C; Yan Q; Chang Z; Liao P; Ma D; Xu L; Zhang H; Lu Y; Liu X; Liu K
    J Pharm Biomed Anal; 2023 Aug; 232():115336. PubMed ID: 37159983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R; Cibulka R; Rajdl D; Racek J
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma asymmetric dimethylarginine in active rheumatoid arthritis: links with oxidative stress and inflammation.
    Kwaśny-Krochin B; Głuszko P; Undas A
    Pol Arch Med Wewn; 2012; 122(6):270-6. PubMed ID: 22549098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production.
    Rodionov RN; Murry DJ; Vaulman SF; Stevens JW; Lentz SR
    J Biol Chem; 2010 Feb; 285(8):5385-91. PubMed ID: 20018850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.
    Böger RH; Zoccali C
    Atheroscler Suppl; 2003 Dec; 4(4):23-8. PubMed ID: 14664899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective clinical trials.
    Szuba A; Podgórski M
    Pharmacol Rep; 2006; 58 Suppl():16-20. PubMed ID: 17332667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.